US Targets German Drug Prices
US Launches Trade Investigation into Germany's Drug Pricing Practices, Threatening Tariffs
Key Points
Greer said the investigation follows prior U.S. pricing negotiations—pointedly citing an April “ground-breaking arrangement” with the United Kingdom and urging Germany to “follow suit with constructive negotiations to address this imbalance.”
A DW report adds context on the scale of the U.S. pricing problem: citing a 2024 RAND study that found prescription drug prices in the United States averaged “2.78 times” those in 33 other countries, with the gap especially large for brand-name drugs.
German policy details underpinning the dispute were more specific than in the summary: Reuters (via Devdiscourse) reported that Germany’s Ministry of Health unveiled an April overhaul aimed at cutting a “looming funding gap by 20 billion euros,” and that the plan to reduce costs would lower insurance premiums by saving “more than €16 billion.”
The same reports place the Germany case in the broader Section 301 track record: Yahoo reported the mechanism has been used before, including “punitive tariffs on China,” and that Washington opened additional Section 301 investigations against the EU and other countries in March—at the time tied to “structural overcapacity.”
The U.S. Trade Representative launched a Section 301 investigation into Germany on June 18, targeting what Washington calls the "persistent underpayment" for innovative medicines. Yahoo Finance reported that USTR Jamieson Greer said American patients should not shoulder "a disproportionate share of global pharmaceutical research and development" costs. The probe could ultimately lead to U.S. tariffs on German imports.
The move follows a May 2025 executive directive from President Trump ordering the USTR to go after foreign price controls. A docket for written public comments opens June 25, with a public hearing set for September 22, according to CNBC.
Germany's €20 Billion Health Crisis Sparked the Fight
Germany's national health insurance system faces a €20 billion funding gap by 2027, growing to €44 billion by 2030. To close it, the Merz government passed draft legislation called the GKV-BStabG in April 2026. The law targets €16.3 billion in savings in 2027 alone, with €1.9 billion carved directly out of pharmaceutical reimbursements through mandatory rebates and price freezes, according to Yahoo Finance.
The USTR called Germany's new law a "serious step backwards." An earlier version of the law included "variable discounts" — rebates that would shift based on healthcare spending. That plan was scrapped after pharma giants including Eli Lilly and Boehringer Ingelheim each threatened to cut up to $1 billion in planned German investments. Fixed discounts replaced them instead.
U.S. Drug Prices Are 2.78 Times Higher Than Peer Nations
The core U.S. argument rests on a stark pricing gap. A 2024 RAND study found that U.S. prescription drug prices average 2.78 times those in 33 other countries. For brand-name drugs specifically, Americans pay 4.22 times more than patients in peer nations. Washington frames this as European governments "freeloading" on American-funded drug research, according to CNBC.
Greer pointed to an April 2026 deal with the United Kingdom as the model Germany should follow. Under that arrangement, the UK agreed to double NHS drug spending from 0.3% to 0.6% of GDP by 2036 in exchange for exemptions from U.S. tariffs. Greer urged Germany to "follow suit with constructive negotiations to address this imbalance," Yahoo Finance reported.
Pharma CEOs Warn of Investment Flight From Germany
Industry leaders are not waiting for tariffs to react. Pfizer CEO Albert Bourla sent a letter directly to Chancellor Friedrich Merz warning that the reforms put "predictability" at risk. Bourla said Pfizer is "reviewing the timing, scope, and future prioritization" of its German investments. Novartis CEO Vas Narasimhan said German policies send the "wrong signal" while the U.S. and China are actively building biotech ecosystems, according to CNBC.
Germany has historically been Europe's most open drug market. Patients there can access 93% of medicines approved by European regulators, compared to just 60% in France. Berlin's Health Minister Nina Warken defended the cuts, saying "every sector must play its part in this reform" and insisting Germany remains an attractive market, Yahoo Finance reported.
Section 301 Could Bring Tariffs on German Cars and Machines
Section 301 of the Trade Act of 1974 gives the USTR broad power to impose tariffs in response to unfair foreign trade practices. The tool was used to impose punitive tariffs on China and, in March 2026, to open probes against the EU and 60 other countries over structural overcapacity, according to Yahoo Finance. The administration shifted toward Section 301 after the Supreme Court blocked Trump's use of emergency economic powers for broad tariffs.
If investigators find Germany's drug pricing discriminatory, analysts expect tariffs of 10% to 12.5% on German imports — most likely targeting cars or industrial machinery, the traditional Section 301 targets. HHS Secretary Robert F. Kennedy Jr. backed the probe, saying "fighting the war against disease is a shared burden" and calling on Germany to "pay its fair share," according to CNBC.
Sentiment
Mostly NegativePublishers
20
Articles
72
Reach
92
